line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.3,ORCHPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,1446507000.0,ORCHPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,345458000.0,ORCHPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,5442226000.0,ORCHPHARMA.NS
EBITDA,2025-03-31 00:00:00,1446507000.0,ORCHPHARMA.NS
EBIT,2025-03-31 00:00:00,1101049000.0,ORCHPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-145401000.0,ORCHPHARMA.NS
Interest Expense,2025-03-31 00:00:00,145401000.0,ORCHPHARMA.NS
Interest Income,2025-03-31 00:00:00,,ORCHPHARMA.NS
Normalized Income,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Total Expenses,2025-03-31 00:00:00,6651290000.0,ORCHPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,ORCHPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,50715929.0,ORCHPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,50715929.0,ORCHPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,19.65,ORCHPHARMA.NS
Basic EPS,2025-03-31 00:00:00,19.65,ORCHPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Net Income Discontinuous Operations,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,996568000.0,ORCHPHARMA.NS
Tax Provision,2025-03-31 00:00:00,-1935000.0,ORCHPHARMA.NS
Pretax Income,2025-03-31 00:00:00,955648000.0,ORCHPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,-1466920000.0,ORCHPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,0.0,ORCHPHARMA.NS
Other Special Charges,2025-03-31 00:00:00,,ORCHPHARMA.NS
Write Off,2025-03-31 00:00:00,,ORCHPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-145401000.0,ORCHPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,ORCHPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,145401000.0,ORCHPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,ORCHPHARMA.NS
Operating Income,2025-03-31 00:00:00,2567969000.0,ORCHPHARMA.NS
Operating Expense,2025-03-31 00:00:00,1209064000.0,ORCHPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,,ORCHPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,345458000.0,ORCHPHARMA.NS
Amortization,2025-03-31 00:00:00,,ORCHPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,345458000.0,ORCHPHARMA.NS
Research And Development,2025-03-31 00:00:00,,ORCHPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,ORCHPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,ORCHPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,ORCHPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,ORCHPHARMA.NS
Gross Profit,2025-03-31 00:00:00,3777033000.0,ORCHPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,5442226000.0,ORCHPHARMA.NS
Total Revenue,2025-03-31 00:00:00,9219259000.0,ORCHPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,9219259000.0,ORCHPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,ORCHPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.3,ORCHPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,1415368000.0,ORCHPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,-6511000.0,ORCHPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,-6511000.0,ORCHPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,332371000.0,ORCHPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,4844591000.0,ORCHPHARMA.NS
EBITDA,2024-03-31 00:00:00,1415368000.0,ORCHPHARMA.NS
EBIT,2024-03-31 00:00:00,1082997000.0,ORCHPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-163545000.0,ORCHPHARMA.NS
Interest Expense,2024-03-31 00:00:00,163545000.0,ORCHPHARMA.NS
Interest Income,2024-03-31 00:00:00,163481000.0,ORCHPHARMA.NS
Normalized Income,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Total Expenses,2024-03-31 00:00:00,5873379000.0,ORCHPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,33417000.0,ORCHPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,48355981.0,ORCHPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,48355981.0,ORCHPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,19.06,ORCHPHARMA.NS
Basic EPS,2024-03-31 00:00:00,19.06,ORCHPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Net Income Discontinuous Operations,2024-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,921665000.0,ORCHPHARMA.NS
Tax Provision,2024-03-31 00:00:00,-31191000.0,ORCHPHARMA.NS
Pretax Income,2024-03-31 00:00:00,919452000.0,ORCHPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,-1237306000.0,ORCHPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,-6511000.0,ORCHPHARMA.NS
Other Special Charges,2024-03-31 00:00:00,1884000.0,ORCHPHARMA.NS
Write Off,2024-03-31 00:00:00,4627000.0,ORCHPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-163545000.0,ORCHPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,3811000.0,ORCHPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,163545000.0,ORCHPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,163481000.0,ORCHPHARMA.NS
Operating Income,2024-03-31 00:00:00,2320303000.0,ORCHPHARMA.NS
Operating Expense,2024-03-31 00:00:00,1028788000.0,ORCHPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,898497000.0,ORCHPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,332371000.0,ORCHPHARMA.NS
Amortization,2024-03-31 00:00:00,11306000.0,ORCHPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,332371000.0,ORCHPHARMA.NS
Research And Development,2024-03-31 00:00:00,70937000.0,ORCHPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,322827000.0,ORCHPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,238563000.0,ORCHPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,84264000.0,ORCHPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,33417000.0,ORCHPHARMA.NS
Gross Profit,2024-03-31 00:00:00,3349091000.0,ORCHPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,4844591000.0,ORCHPHARMA.NS
Total Revenue,2024-03-31 00:00:00,8193682000.0,ORCHPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,8193682000.0,ORCHPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,0.0,ORCHPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.0,ORCHPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,1022590000.0,ORCHPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,400004000.0,ORCHPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,400004000.0,ORCHPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,530934000.0,ORCHPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,547868000.0,ORCHPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,3971760000.0,ORCHPHARMA.NS
EBITDA,2023-03-31 00:00:00,1422594000.0,ORCHPHARMA.NS
EBIT,2023-03-31 00:00:00,874726000.0,ORCHPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,-322842000.0,ORCHPHARMA.NS
Interest Expense,2023-03-31 00:00:00,322257000.0,ORCHPHARMA.NS
Interest Income,2023-03-31 00:00:00,6180000.0,ORCHPHARMA.NS
Normalized Income,2023-03-31 00:00:00,130930000.0,ORCHPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,463183000.0,ORCHPHARMA.NS
Total Expenses,2023-03-31 00:00:00,6362294000.0,ORCHPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,10160000.0,ORCHPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,40816400.0,ORCHPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,40816400.0,ORCHPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,11.35,ORCHPHARMA.NS
Basic EPS,2023-03-31 00:00:00,11.35,ORCHPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,463183000.0,ORCHPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,463183000.0,ORCHPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income,2023-03-31 00:00:00,463183000.0,ORCHPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,463183000.0,ORCHPHARMA.NS
Net Income Discontinuous Operations,2023-03-31 00:00:00,-67751000.0,ORCHPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,530934000.0,ORCHPHARMA.NS
Tax Provision,2023-03-31 00:00:00,0.0,ORCHPHARMA.NS
Pretax Income,2023-03-31 00:00:00,552469000.0,ORCHPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,126602000.0,ORCHPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,399850000.0,ORCHPHARMA.NS
Other Special Charges,2023-03-31 00:00:00,-399850000.0,ORCHPHARMA.NS
Write Off,2023-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-322842000.0,ORCHPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,6765000.0,ORCHPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,322257000.0,ORCHPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,6180000.0,ORCHPHARMA.NS
Operating Income,2023-03-31 00:00:00,296690000.0,ORCHPHARMA.NS
Operating Expense,2023-03-31 00:00:00,2390534000.0,ORCHPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,859732000.0,ORCHPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,547868000.0,ORCHPHARMA.NS
Amortization,2023-03-31 00:00:00,78000.0,ORCHPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,547790000.0,ORCHPHARMA.NS
Research And Development,2023-03-31 00:00:00,63621000.0,ORCHPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,231228000.0,ORCHPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,143363000.0,ORCHPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,87865000.0,ORCHPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,10160000.0,ORCHPHARMA.NS
Gross Profit,2023-03-31 00:00:00,2687224000.0,ORCHPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,3971760000.0,ORCHPHARMA.NS
Total Revenue,2023-03-31 00:00:00,6658984000.0,ORCHPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,6658984000.0,ORCHPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,0.0,ORCHPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.0,ORCHPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,616248000.0,ORCHPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,5128000.0,ORCHPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,5128000.0,ORCHPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,-604214000.0,ORCHPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,870246000.0,ORCHPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,3262850000.0,ORCHPHARMA.NS
EBITDA,2022-03-31 00:00:00,621376000.0,ORCHPHARMA.NS
EBIT,2022-03-31 00:00:00,-248870000.0,ORCHPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-330372000.0,ORCHPHARMA.NS
Interest Expense,2022-03-31 00:00:00,320117000.0,ORCHPHARMA.NS
Interest Income,2022-03-31 00:00:00,4188000.0,ORCHPHARMA.NS
Normalized Income,2022-03-31 00:00:00,-609342000.0,ORCHPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,-19512000.0,ORCHPHARMA.NS
Total Expenses,2022-03-31 00:00:00,5920030000.0,ORCHPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,15809000.0,ORCHPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,40816400.0,ORCHPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,40816400.0,ORCHPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,-0.48,ORCHPHARMA.NS
Basic EPS,2022-03-31 00:00:00,-0.48,ORCHPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,-19512000.0,ORCHPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,-19512000.0,ORCHPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,ORCHPHARMA.NS
Net Income,2022-03-31 00:00:00,-19512000.0,ORCHPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,-19512000.0,ORCHPHARMA.NS
Net Income Discontinuous Operations,2022-03-31 00:00:00,584702000.0,ORCHPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,-604214000.0,ORCHPHARMA.NS
Tax Provision,2022-03-31 00:00:00,0.0,ORCHPHARMA.NS
Pretax Income,2022-03-31 00:00:00,-568987000.0,ORCHPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,4895000.0,ORCHPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,4000.0,ORCHPHARMA.NS
Other Special Charges,2022-03-31 00:00:00,-4000.0,ORCHPHARMA.NS
Write Off,2022-03-31 00:00:00,,ORCHPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-330372000.0,ORCHPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,14443000.0,ORCHPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,320117000.0,ORCHPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,4188000.0,ORCHPHARMA.NS
Operating Income,2022-03-31 00:00:00,-324456000.0,ORCHPHARMA.NS
Operating Expense,2022-03-31 00:00:00,2657180000.0,ORCHPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,747415000.0,ORCHPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,870246000.0,ORCHPHARMA.NS
Amortization,2022-03-31 00:00:00,313000.0,ORCHPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,869933000.0,ORCHPHARMA.NS
Research And Development,2022-03-31 00:00:00,66263000.0,ORCHPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,309031000.0,ORCHPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,222617000.0,ORCHPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,86414000.0,ORCHPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,15809000.0,ORCHPHARMA.NS
Gross Profit,2022-03-31 00:00:00,2332724000.0,ORCHPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,3262850000.0,ORCHPHARMA.NS
Total Revenue,2022-03-31 00:00:00,5595574000.0,ORCHPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,5595574000.0,ORCHPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,ORCHPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,ORCHPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,ORCHPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,ORCHPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,ORCHPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,ORCHPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,ORCHPHARMA.NS
EBITDA,2021-03-31 00:00:00,,ORCHPHARMA.NS
EBIT,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,ORCHPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,ORCHPHARMA.NS
Interest Income,2021-03-31 00:00:00,7326000.0,ORCHPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,ORCHPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,ORCHPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,15061000.0,ORCHPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,,ORCHPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,,ORCHPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,,ORCHPHARMA.NS
Basic EPS,2021-03-31 00:00:00,,ORCHPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,ORCHPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income Discontinuous Operations,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,ORCHPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,ORCHPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,ORCHPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,ORCHPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,ORCHPHARMA.NS
Other Special Charges,2021-03-31 00:00:00,650000.0,ORCHPHARMA.NS
Write Off,2021-03-31 00:00:00,,ORCHPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,ORCHPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,8708000.0,ORCHPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,ORCHPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,7326000.0,ORCHPHARMA.NS
Operating Income,2021-03-31 00:00:00,,ORCHPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,ORCHPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,498681000.0,ORCHPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,ORCHPHARMA.NS
Amortization,2021-03-31 00:00:00,318000.0,ORCHPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,ORCHPHARMA.NS
Research And Development,2021-03-31 00:00:00,48097000.0,ORCHPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,263539000.0,ORCHPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,134550000.0,ORCHPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,128989000.0,ORCHPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,15061000.0,ORCHPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,ORCHPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,ORCHPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,ORCHPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,ORCHPHARMA.NS
